Novo Nordisk stock price forecast: $45.27 support as NVO remains stable

Traders Union
All News
Financial News
Novo Nordisk slips 0.07% to $47.39

Highlights

UK approval of oral Wegovy expands Novo Nordisk's obesity market footprint and supports future revenue growth opportunities.
Novo Nordisk advanced its DKK 15 billion buyback and strengthened sustainability initiatives via a partnership to restore Amazon rainforest.
NVO trades in a consolidation range, with strong buy signals from most momentum indicators and a short-term target of $45.19–$49.59.

Expansion prospects strengthen as UK approvals and buybacks drive sentiment

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved the oral formulation of Wegovy for weight management in adults with obesity or related health conditions, as reported by Finance Yahoo. This regulatory milestone clears the path for Novo Nordisk to access the UK market with a new delivery mode, directly expanding its potential customer base and strengthening its commercial footprint. Novo Nordisk also advanced its DKK 15 billion share buyback program by repurchasing over one million B shares between June 15 and 19, according to Tipranks, while a recent partnership with re.green was established to restore 500 hectares of Amazon rainforest, supporting its sustainability commitments as confirmed by Sustainabilitymag.

Momentum divergence persists as price holds above key averages

On the technical front, NVO trades above its 20- and 50-day moving averages but remains below the 200-day, framing recent gains within a longer-term resistance band. The Ichimoku Kijun at $45.27 provides immediate support, while the expected trading range in the coming sessions is $45.19 to $49.59. Relative Strength Index (RSI) stands at 69.05, near the overbought threshold, while Stochastic RSI is oversold and Commodity Channel Index (CCI) signals continued buying interest. Bull/Bear Power indicates buyers remain dominant intraday, Moving Average Convergence Divergence (MACD) and Average Directional Index (ADX) confirm buy pressure, and the Awesome Oscillator is neutral—highlighting the current divergence among momentum indicators and suggesting a degree of caution despite the positive momentum bias.

Upward bias likely as support holds within range-bound outlook

In the short term, NVO is likely to consolidate within a volatility band spanning $45.19 to $49.59. Should price action hold above the $45.27 support level, a move toward the upper end of this range is likely, particularly if buying momentum persists. Conversely, a break below the Ichimoku Kijun could open the door to additional downside risk. The baseline expectation is for price to remain range-bound over the next several sessions, with a greater likelihood of upward bias based on current momentum probabilities.

Viktoras Karapetjanc, expert at Traders Union, sees Novo Nordisk’s position strengthening on both fundamental and sentiment fronts. He notes that the MHRA’s approval for oral Wegovy is a meaningful inflow catalyst, expanding access and priming new revenue potential. Sustainability work and continued share buybacks reinforce the long-term outlook and underpin ongoing institutional support. Technically, with price action above key short- and medium-term averages, Karapetjanc expects a constructive range-bound phase, with upside favored if buying pressure holds. "Novo Nordisk’s combination of regulatory momentum, sustainability, and buybacks creates a strong platform for further gains if current support levels are sustained."

Previously it was reported that Novo Nordisk shares maintained a bullish technical setup, supported by constructive price action and positive corporate developments. With the newly approved UK launch of oral Wegovy and ongoing buyback activity, momentum is reinforced and a sustained close above the $49.59 level would be a critical indicator for potential breakout and further upside.

Source of Data: NVO Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.